The importance of implementing proper selection of excipients in lupus clinical trials

Lupus

Volumn 23, Issue 7, 2014, Pages 609-614

  Muller, S ^a   Wallace, D J ^b  

^a INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autophagy; Clinical trials; Excipients; P140 Lupuzor; Systemic lupus erythematosus; Trehalose

Indexed keywords

EXCIPIENT; FORIGERIMOD; MANNITOL; PLACEBO; TREHALOSE; PEPTIDE FRAGMENT; SPLICEOSOMAL PEPTIDE P140;

AUTOIMMUNE DISEASE; AUTOPHAGY; BLOOD; CLINICAL EVALUATION; DIABETES MELLITUS; DRUG EFFICACY; DRUG FORMULATION; DRUG INHIBITION; DRUG SAFETY; HUMAN; LUPUS VULGARIS; NEOPLASM; NEUROLOGIC DISEASE; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG INTERACTION; LUPUS ERYTHEMATOSUS, SYSTEMIC;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; EXCIPIENTS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PEPTIDE FRAGMENTS; TREHALOSE;

EID: 84903594342     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314525249     Document Type: Review

References (22)

1. Ohtake S, Wang YJ. Trehalose: Current use and future applications. J Pharm Sci 2011; 100: 2020-2053.
2. Jain NK, Roy I. Effect of trehalose on protein structure. Protein Sci 2009; 18: 24-36.
3. Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem 2007; 282: 5641-5652.
4. Izmitli A, Schebor C, McGovern MP, Reddy AS, Abbott NL, de Pablo JJ. Effect of trehalose on the interaction of Alzheimer's Abpeptide and anionic lipid monolayers. Biochim Biophys Acta 2011; 1808: 26-33.
5. Zhao J, Wang S, Bao J, et al. Trehalose maintains bioactivity and promotes sustained release of BMP-2 from lyophilized CDHA scaffolds for enhanced osteogenesis in vitro and in vivo. PLoS One 2013; 8: e54645.
6. Aguib Y, Heiseke A, Gilch S, et al. Autophagy induction by trehalose counteracts cellular prion infection. Autophagy 2009; 5: 361-369.
7. Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. Nature 2011; 469: 323-335.
8. Deretic V, Saitoh T, Akira S. Autophagy in infection, inflammation and immunity. Nat Rev Immunol 2013; 13: 722-737.
9. Klionsky DJ, Codogno P. The mechanism and physiological function of macroautophagy. J Innate Immun 2013; 5: 427-433.
10. Kim SI, Lee WK, Kang SS, et al. Suppression of autophagy and activation of glycogen synthase kinase 3beta facilitate the aggregate formation of tau. Korean J Physiol Pharmacol 2011; 15: 107-114.
11. Krüger U, Wang Y, Kumar S, Mandelkow EM. Autophagic degradation of tau in primary neurons and its enhancement by trehalose. Neurobiol Aging 2012; 33: 2291-2305.
12. Tang C.H., Su LY, Tseng WC. Using trehalose delivered by the intramuscular injection of plasmid DNA as an adjuvant for transgene expression. J Gene Med 2009; 11: 250-256.
13. Zimmer R, Wallace DJ, Muller S. Randomized, double-blind, placebo- controlled studies of P140 peptide in mannitol (Lupuzor) and trehalose (Forigerimod) in patients with SLE. Arthritis Rheum 2012; 64(Suppl 10): 2620.
14. Muller S, Monneaux F, Schall N, et al. Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus. Results of an early phase II clinical trial. Arthritis Rheum 2008; 58: 3873-3883.
15. Zimmer R, Scherbarth HR, Rillo OL, Gomez-Reino J, Muller S. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: A randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis 2013; 72: 1830-1835.
16. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo- controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918-3930.
17. Page N, Gros F, Schall N, et al. HSC70 blockade by the therapeutic peptide P140 affects autophagic processes and endogenous MHCII presentation in murine lupus. Ann Rheum Dis 2011; 70: 837-843.
18. Monneaux F, Parietti V, Briand J-P, Muller S. Importance of spliceosomal RNP1 motif for intermolecular T-B cell spreading and tolerance restoration in lupus. Arthritis Res Ther 2007; 9: R111.
19. Gros F, Arnold J, Page N, et al. Macroautophagy is deregulated in murine and human lupus T lymphocytes. Autophagy 2012; 8: 1113-1123.
20. Massey AC, Kaushik S, Sovak G, Kiffin R, Cuervo AM. Consequences of the selective blockage of chaperone-mediated autophagy. Proc Natl Acad Sci USA 2006; 103: 5805-5810.
21. Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell 2010; 140: 313-326.
22. Schall N, Page N, Macri M, Chaloin O, Briand JP, Muller S. Peptide-based approaches to treat lupus and other autoimmune diseases. J Autoimmunity 2012; 39: 143-153.